Clinical Trial Detail

NCT ID	NCT04260802
Title	A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Recruitment	Not yet recruiting
Gender	both
Phase	Phase Ib/II
Variant Requirements	Yes
Sponsors	Ocellaris Pharma, Inc.
Indications	sarcoma ovarian cancer Merkel cell carcinoma transitional cell carcinoma skin squamous cell carcinoma urinary bladder cancer triple-receptor negative breast cancer head and neck squamous cell carcinoma cervical cancer hepatocellular carcinoma Advanced Solid Tumor stomach cancer renal cell carcinoma lung non-small cell carcinoma
Therapies	OC-001 + unspecified PD-L1 antibody OC-001 + unspecified PD-1 antibody OC-001
Age Groups:	senior adult